We do have COVID-19 IgG/IgM Immunoassay rapid tests to fight the pandemic
0

Tu carrito está vacío

It begins in Tokyo - History of TXA, a drug which saves millions of mother lives from postpartum hemorrhage

diciembre 26, 2017

It begins in Tokyo - History of TXA, a drug which saves millions of mother lives from postpartum hemorrhage

It started with a Japanese wife and husband team in Tokyo in the 1950s. Postpartum hemorrhage was a leading cause of maternal death in Japan at the time, and Utako and Shosuke Okamoto set out to identify a drug that could reduce the number of mothers dying during childbirth. Resources were hard to find at the time, especially for something like blood research. On top of that, the heavily male-dominated medical field meant that Utako had to work twice as hard and long for the chance to even be acknowledged for her accomplishments. After giving birth, she had to bring her baby into the lab because the system did not support working mothers.

Their hard work paid off. They knew that there was already an enzyme in the blood that broke down clots - they just needed to figure out how to get that enzyme going. The amino acid lysine was found to be effective, but they kept looking, thinking there must be more. In 1962, they published in the Keio Journal of Medicine about a drug called tranexamic acid (TXA), which they discovered to be 27 times more powerful than a previous lysine-based drug. Despite this, local obstetricians were not too interested and tranexamic acid was eventually marketed to easy heavy menstrual bleeding and bleeding from procedures such as tooth extractions.

Years later, research finally recognized the full extent of what TXA could do for trauma patients. In 2010, results of the CRASH-2 trial was published in the Lancet. Researchers found that out of over 10,000 study participants, TXA significantly reduced the risk of death due to bleeding. Earlier this year, the WOMAN trial focused specifically on pregnant women and found that TXA significantly reduced death due to postpartum hemorrhage as well. Utako passed away shortly after recruiting for the WOMAN study reached its goal of 20,000 participants, but she said she already knew the results. “I am absolutely sure that it’s going to be effective - I don’t need the research to know this.”

By Vivian Shih


Dejar un comentario

Los comentarios se aprobarán antes de mostrarse.


Ver artículo completo

Antiretroviral Pouch Leads Innovation in Pediatric HIV Care
Antiretroviral Pouch Leads Innovation in Pediatric HIV Care

febrero 24, 2021

Ver artículo completo
COVID-19 Paints Bleak Picture for Maternal and Child Malnutrition
COVID-19 Paints Bleak Picture for Maternal and Child Malnutrition

febrero 07, 2021

The global pandemic has pushed progress on  maternal and child nutrition back by several years. Economic recessions and interrupted food supply chains have caused delays to global nutrition targets for stunting, wasting, maternal anaemia, and breastfeeding by 2025 -- threatening to exacerbate maternal and child malnutrition in low and middle-income countries.
Ver artículo completo
High-Fidelity Lactation Simulators Hit the Market and Spur More Realistic Teaching on Breast Health and Lactation
High-Fidelity Lactation Simulators Hit the Market and Spur More Realistic Teaching on Breast Health and Lactation

enero 03, 2021

Maternova is proud to partner with LiquidGoldConcept, a women-founded team of experts, who have created a high-fidelity lactation simulator capable of modeling a wide variety of breastfeeding complications. The world’s first realistic  and wearable  breastfeeding training tool for parents, students and medical providers, LiquidGoldConcept’s lactation simulation models simulate a wide range of normal (and abnormal) conditions that include early stage mastitis, engorgement, plugged ducts, as well as nipple damages and fissures.
Ver artículo completo
Noticias y actualizaciones

Regístrate gratis para obtener lo último en ventas, nuevos lanzamientos y más…

maternal and newborn health news